Analyst consensus rating
CytomX Therapeutics Analyst Rating: Strong Buy
Direct answer
CytomX Therapeutics's consensus rating is Strong Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $12.25.
Forecast evidence checked October 18, 2026.
Get free CytomX Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.28
- Average price target
- $12.25
- High price target
- $16.00
- Low price target
- $6.00
- Low target gap
- +163.2%
- Target upside
- +437.3%
- High target gap
- +601.8%
- Target range width
- 438.6%
- Consensus rating
- Strong Buy
- Analysts
- 8
- Evidence date
- October 18, 2026
- Valid through
- October 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for CytomX Therapeutics?
CytomX Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $12.25.
How far are CytomX Therapeutics's low and high targets from the recorded price?
The low target implies +163.2%, while the high target implies +601.8%.
How many analysts are included in CytomX Therapeutics's consensus?
The verified consensus includes 8 analysts.
How is CytomX Therapeutics's target upside or downside calculated?
The average target of $12.25 is divided by the recorded price of $2.28, then one is subtracted to produce +437.3%. This does not guarantee a future return.
When was CytomX Therapeutics's analyst forecast verified?
The data was verified on 2026-10-18. The dataset is valid through 2026-10-25.